cheapest alternative (Simvastatin) should be prescribed. We investigate whether Simvastatin and Atorvastatin, the most commonly …

Objective: The CARDS trial, a multicentre, randomized, controlled trial, found that atorvastatin 10 mg/day for patients …) events, including stroke. We estimated the cost effectiveness of atorvastatin as primary prevention against CV disease from …) model to evaluate long-term costs and outcomes for atorvastatin 10 mg/day versus no HMG-CoA reductase inhibitor (statin …

Atorvastatin is a lipid-lowering agent that has been evaluated in a number of primary and secondary intervention … studies. In the primary prevention trials ASCOT-LLA and CARDS, atorvastatin 10 mg/day significantly reduced cardiovascular … atorvastatin was associated with incremental cost-effectiveness ratios (ICERs) of _11_693 (UK) and _12_673 (Sweden) per event …

Introduction: This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus … atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who … did not reach target cholesterol levels on their current atorvastatin dosage. The primary analysis focused on 65-year …

. Interventions: Forty-eight patients received oral atorvastatin 10 mg/day, 32 received fluvastatin 40 mg/day, 44 received simvastatin …, were reached in 62.5%, 43.8%, 45.5% and 40.5% of patients treated with atorvastatin, fluvastatin, simvastatin and …, was _424.3 for atorvastatin, _503.5 for fluvastatin, _527.0 for simvastatin and _683.4 for pravastatin. The incremental CE …

established CHD or risk factors for CHD and the type and severity of dyslipidaemia. Atorvastatin has greater LDL …-cholesterol-lowering activity than other members of its class; it also has greater triglyceride-lowering properties. Atorvastatin appears to have a …. Available evidence from modelling studies or economic assessments of clinical trial data suggests that atorvastatin is more cost …

treating patients to achieve NCEP goals using 4 reductase inhibitors: atorvastatin, simvastatin, lovastatin and fluvastatin … colestipol was added. Main outcome measures and results: Patients treated with atorvastatin, compared with other reductase … with atorvastatin [$US1064; 95% confidence interval (CI): $US953 to $US1176] compared with simvastatin ($US1471; 95% CI …